Showing results (71-80 of 245) with videos related to

Sort By:
Pageof 25
Organic Letters|June 4, 2010
Enantioselective total synthesis of the selective PI3 kinase inhibitor liphagalEnrique Alvarez-Manzaneda, Rachid Chahboun, Esteban Alvarez, et al.
Plos One|September 8, 2011
Detection, properties, and frequency of local calcium release from the sarcoplasmic reticulum in teleost cardiomyocytesAnna Llach, Cristina E Molina, Enrique Alvarez-Lacalle, et al.
Archives of Neurology|August 29, 2012
Association of neuromyelitis optica with severe and intractable painPeiqing Qian, Samantha Lancia, Enrique Alvarez, et al.
The American Journal of Psychiatry|June 3, 2005
Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorderJoaquim Soler, Juan Carlos Pascual, Josefa Campins, et al.
Clinical Practice and Epidemiology in Mental Health : CP & EMH|November 23, 2012
Broadening of Generalized Anxiety Disorders Definition Does not Affect the Response to Psychiatric Care: Findings from the Observational ADAN StudyEnrique Alvarez, Jose L Carrasco, José M Olivares, et al.
IEEE Journal of Solid-State Circuits|December 19, 2018
High-Density Redox Amplified Coulostatic Discharge-Based Biosensor ArrayAlexander C Sun, Enrique Alvarez-Fontecilla, A G Venkatesh, et al.
Annals of Clinical and Translational Neurology|August 9, 2020
Serious safety events in rituximab-treated multiple sclerosis and related disordersBrandi L Vollmer, Asya I Wallach, John R Corboy, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 26, 2019
Subjective cognitive concern in multiple sclerosis is associated with reduced thalamic and cortical gray matter volumesIsaiah Kletenik, Enrique Alvarez, Justin M Honce, et al.
Annals of Clinical and Translational Neurology|March 9, 2019
Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatmentBrandi L Vollmer, Kavita V Nair, Stefan Sillau, et al.
Plos One|April 5, 2013
The role of systematic reviews in pharmacovigilance planning and Clinical Trials Authorisation application: example from the SLEEPS trialCarrol Gamble, Andrew Wolf, Ian Sinha, et al.
Pageof 25